News

For people struggling with both diabetes and a common type of heart failure, the weight-loss drug Wegovy may do more for their health than help them shed pounds, new research suggests.

Before his heart transplant, Robert Johnson had a hard time even cutting his grass. Now, after receiving a heart transplant at Saint Luke's Mid America Heart Institute, he is back to enjoying physical activities, like golf.

A new study led by Dr. Mikhail Kosiborod found patients with obesity-related heart failure and type 2 diabetes had significant improvement in symptoms and physical limitations when taking semaglutide.

The popular weight loss drug Wegovy seems to provide more health benefits for people who have diabetes and a common kind of heart failure than just helping take off the pounds, according to the results from the STEP HFpEF DM trial.

A new study led by Dr. Mikhail Kosiborod found patients with obesity-related heart failure and diabetes had a significant improvement in symptoms when taking semaglutide.

Saint Luke’s Mid America Heart Institute today announced results from the STEP HFpEF DM trial.

Dr. James O'Keefe weighs in on a new study that found eating more than a dozen fortified eggs a week did not negatively affect cholesterol levels.

As a winner of the Press Ganey HX Guardian of Excellence Award®, Hedrick is in the top 5% of healthcare providers nationwide in delivering rehabilitation services in the last year.

Cardiovascular Business spoke with Dr. Timothy Bateman about his views on SPECT advances and its longevity in the coming years.

New study led by Saint Luke’s Mid America Heart Institute cardiologists reveals lower risk of all-cause and cause-specific mortality associated with higher docosahexaenoic acid (DHA) blood levels